Protocol name |
Indication |
Induction |
Consolidation |
Maintenance |
GRIFFIN
ID 3919 Multiple myeloma RVd (lenalidomide bortezomib dexamethasone) GRIFFIN overview
|
Newly diagnosed multiple myeloma patients (MM) who are eligible for autologous stem cell transplantation (ASCT)
|
Frequency: 21 days
Cycles: 4
Lenalidomide 25 mg PO D1-14
Bortezomib 1.3 mg/m2 SC D1,4,8,11
Dexamethasone 20 mg PO D1,2,8,9,15,16
|
Frequency: 21 days
Cycles: 2 post-ASCT
Lenalidomide 25 mg PO D1-14
Bortezomib 1.3 mg/m2 SC D1,4,8,11
Dexamethasone 20 mg PO D1,2,8,9,15,16
|
Frequency: 28 days
Cycles: 7-32
Lenalidomide 10 mg PO D1-21
(increasing to 15 mg after 3 cycles if tolerated)
|
IFM 2009
ID 3959 Multiple myeloma RVd (lenalidomide bortezomib dexamethasone) IFM 2009 overview
|
Newly diagnosed MM patients who are eligible for ASCT
|
Frequency: 21 days
Cycles: 3
Lenalidomide 25 mg PO D1-14
Bortezomib 1.3 mg/m2 SC D1,4,8,11
Dexamethasone 20 mg PO D1,2,4,5,8,9,11,12
|
Frequency: 21 days
Cycles: 2 post-ASCT or 5 (RVd alone - no transplant)
Lenalidomide 25 mg PO D1-14
Bortezomib 1.3 mg/m2 SC D1,4,8,11
Dexamethasone 10 mg PO D1,2,4,5,8,9,11,12
|
Frequency: 28 days
Cycles: 12 (1 year)
Lenalidomide 10 mg PO D1-28
(increasing to 15 mg after 3 cycles if tolerated)
|
PETHEMA
ID 3936 Multiple myeloma RVd (lenalidomide bortezomib dexamethasone) PETHEMA overview
|
Newly diagnosed MM patients who are eligible for ASCT
|
Frequency: 28 days
Cycles: 6
Lenalidomide 25 mg PO D1-21
Bortezomib 1.3 mg/m2 SC D1,4,8,11
Dexamethasone 40 mg PO D1-4 and D9-12
|
Frequency: 28 days
Cycles: 2 post-ASCT
Lenalidomide 25 mg PO D1-21
Bortezomib 1.3 mg/m2 SC D1,4,8,11
Dexamethasone 40 mg PO D1-4 and D9-12
|
None |
SWOG S0777
ID 3911 Multiple myeloma RVd (lenalidomide bortezomib dexamethasone) SWOG S0777 overview
|
Newly diagnosed MM patients
|
Frequency: 21 days
Cycles: 8
Lenalidomide 25 mg PO D1-14
Bortezomib 1.3 mg/m2 SC D1,4,8,11
Dexamethasone 20 mg PO D1,2,4,5,8,9,11,12
|
None |
Frequency: 28 days
Cycles: on-going
Lenalidomide 25 mg PO D1-21
Dexamethasone 40 mg PO D1,8,15,22
|
RVd-lite
ID 3917 Multiple myeloma RVd-lite (lenalidomide bortezomib dexamethasone) overview
|
Newly diagnosed MM patients who are transplant ineligible
|
Frequency: 35 days
Cycles: 9
Lenalidomide 15 mg PO D1-21
Bortezomib 1.3 mg/m2 SC D1,8,15,22
Dexamethasone:
≤ 75 yr: 20 mg PO D1,2,8,9,15,16,22,23
> 75 yr: 20 mg PO D1,8,15,22
|
Frequency: 28 days
Cycles: 6
Lenalidomide 15 mg PO D1-21
Bortezomib 1.3 mg/m2 SC D1,15
|
Continue as per clinician discretion |